Table 1.
Characteristic | EBC all | EBC – relapsed or follow-up ≥5 years | EBC – relapsed or follow-up ≥6 years | MBC |
---|---|---|---|---|
Number | 590 | 443 | 319 | 109 |
Age, mean (range) | 42 (29–50) | 42 (29–50) | 42 (29–50) | 39 (22–53) |
Tumor size, n (%) | ||||
<2 cm | 35 (5.9) | 23 (5.2) | 11 (3.5%) | — |
2–5 cm | 396 (67.1) | 285 (64.3) | 203 (63.6%) | |
>5 cm | 159 (27) | 135 (30.5) | 105 (32.9%) | |
Grade, n (%) | ||||
I | 74 (13) | 63 (14) | 46 (14) | — |
II | 300 (51) | 224 (51) | 162 (51) | |
III | 115 (19) | 89 (20) | 73 (23) | |
Unknown | 101 (17) | 67 (15) | 38 (12) | |
Lymph node status, n (%) | ||||
0 | 248 (42) | 166 (37.5) | 106 (33) | — |
1–3 | 157 (27) | 121 (27.5) | 83 (26) | |
>3 | 185 (31) | 156 (35) | 130 (41) | |
HER2, n (%) | ||||
Positive | 108 (18) | 90 (20.5) | 76 (24) | — |
Negative | 388 (66) | 298 (67) | 210 (66) | |
Unknown | 94 (16) | 55 (12.5) | 33 (10) | |
ER, n (%) | ||||
Positive | 552 (93.6) | 410 (92.6) | 297 (93) | — |
Negative | 37 (6.3) | 32 (7.2) | 22 (7) | |
Unknown | 1 (0.2) | 1 (0.2) | 0 (0) | |
PR, n (%) | ||||
Positive | 545 (92.4) | 405 (91.4) | 291 (91) | — |
Negative | 44 (7.4) | 37 (8.4) | 28 (9) | |
Unknown | 1 (0.2) | 1 (0.2) | 0 (0) | |
Treatment arm, n (%) | ||||
A | 186 (31.5) | 142 (32.0) | 106 (33.2) | — |
B | 216 (36.6) | 158 (35.7) | 111 (34.8) | |
C | 188 (31.9) | 143 (32.3) | 102 (32.0) | |
Dominant metastatic site, n (%) | ||||
Soft tissue | — | — | — | 79 (72.5) |
Bone | 17 (15.6) | |||
Viscera | 13 (11.9) | |||
Prior systemic treatment, n (%) | ||||
No | — | — | — | 69 (63.3) |
Yes | 40 (36.7) |
NOTE: Treatment arm A: not in luteal phase at the time of trial entry, randomized to luteal phase surgery; treatment arm B: not in luteal phase at the time of trial entry, randomized to immediate, non-luteal phase surgery; and treatment arm C: in luteal phase at the time of trial entry, immediate surgery in luteal phase.
Abbreviation: PR, progesterone receptor.